<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Cryoablation</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Patent update: Pacira Cryotech seek to repurpose its analgesic iovera technology for treating arrhythmia</title>
      <description>
        <![CDATA[Pacira Cryotech Inc. reported the filing of a patent for a hand-held cryogenic treatment system with a probe configured to apply a cryogenic therapy to one or more nerves, such as the nerves of the stellate ganglion and autonomic tissue peripheral to the stellate ganglion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700822</guid>
      <pubDate>Thu, 07 Sep 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700822-patent-update-pacira-cryotech-seek-to-repurpose-its-analgesic-iovera-technology-for-treating-arrhythmia</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Pacira-Cryotech-7sept23.webp?t=1694122126" type="image/jpeg" medium="image" fileSize="124545">
        <media:title type="plain">Pacira Cryotech cryogenic treatment</media:title>
        <media:description type="plain">WO2023164433-A1, “Cryogenic therapy systems and methods.”Assignee: Pacira Cryotech Inc.Inventors: Ham, Jared; Slonin, Jonathan; Spranger, John; Winston, RoyIPC Codes: A61B 17/34; A61F 7/12; A61B 18/00; A61B 18/02; A61F 7/00Publication date: Aug. 31, 2023Earliest priority details: US2022313698, Feb. 24, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Innovahealth Partners takes controlling stake in Channel Medsystems</title>
      <description>
        <![CDATA[Channel Medsystems Inc. completed a fundraising round to enable the nationwide commercial launch of its Cerene cryotherapy device for treatment of heavy menstrual bleeding thanks to a $26 million investment by Innovahealth Partners LP. The investment is among the largest New York-based Innovahealth has made in any company so far and makes it Channel’s largest shareholder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511257</guid>
      <pubDate>Thu, 09 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511257-innovahealth-partners-takes-controlling-stake-in-channel-medsystems</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/09-09-Channel-Medsystems-Cerene.webp?t=1631228218" type="image/png" medium="image" fileSize="58406">
        <media:title type="plain">Cerene image</media:title>
        <media:description type="plain">Cerene cryoablation device. Credit: Channel Medsystems Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Johns Hopkins cryoablation study could boost procedure to first-line in early kidney cancer</title>
      <description>
        <![CDATA[A long-term clinical trial comparing minimally invasive cryoablation to surgery to treat early stage kidney cancer patients has found that the former offers comparable rates of survival and fewer complications. Johns Hopkins researchers published the 10-year survival data for 134 patients in the June 9, 2020, issue of <em>Radiology</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435681</guid>
      <pubDate>Tue, 09 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435681-johns-hopkins-cryoablation-study-could-boost-procedure-to-first-line-in-early-kidney-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-cancer-tumor.webp?t=1745263246" type="image/jpeg" medium="image" fileSize="344153">
        <media:title type="plain">Illustration of tumor on kidney</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA OKs new indications for Icecure’s cryoablation technology, new Multisense system</title>
      <description>
        <![CDATA[Caesarea, Israel-based Icecure Medical Ltd. has won the FDA&rsquo;s nod for additional indications for its cryoablation technology, paving the way for use in kidney, liver, ear, nose and throat and new neurology indications. The agency also cleared Icecure&rsquo;s new Multisense system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432245</guid>
      <pubDate>Tue, 07 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432245-fda-oks-new-indications-for-icecures-cryoablation-technology-new-multisense-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-7-Icecure-Medical-multisense-gun.webp?t=1578435419" type="image/png" medium="image" fileSize="1442070">
        <media:title type="plain">1-7-Icecure-Medical-multisense-gun.png</media:title>
        <media:description type="plain">Cryoablation technology. Credit: Icecure Medical Ltd.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
